Global CAR-NK Cell Therapy Supply, Demand and Key Producers, 2026-2032
The global CAR-NK Cell Therapy market size is expected to reach $ 3547 million by 2032, rising at a market growth of 5.6% CAGR during the forecast period (2026-2032).
CAR-NK cell therapy is an advanced cellular therapy technique that combines the natural anticancer ability of natural killer (NK) cells with the specific targeting function of chimeric antigen receptors (CARs). Through genetic engineering, CAR structures capable of recognizing specific tumor antigens are introduced into NK cells, thereby enhancing their targeting ability and killing power. This therapy has shown great potential in treating various types of cancers, including hematological tumors and solid tumors. CAR-NK cell therapy has lower toxic and side effects and better safety, making it a promising supplement or alternative to CAR-T cell therapy.
Market Drivers
Superior Safety and ?Off-the-Shelf? Potential over CAR-T therapies is a critical driver. CAR-NK cells carry a significantly lower risk of cytokine release syndrome (CRS), neurotoxicity, and graft-versus-host disease (GvHD). Furthermore, they can be developed as allogeneic, ?off-the-shelf? products from healthy donors, unlike patient-specific CAR-T cells. This enables faster, more scalable, and cost-effective production.
Technological Advancements and Clinical Progress are accelerating market growth. These include the development of genetically engineered CAR-NK cells, integration of induced pluripotent stem cell (iPSC)-derived NK cells for mass production, and improved cryopreservation techniques. The pipeline is robust, with numerous companies advancing therapies into late-stage clinical trials.
This report studies the global CAR-NK Cell Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for CAR-NK Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of CAR-NK Cell Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global CAR-NK Cell Therapy total market, 2021-2032, (USD Million)
Global CAR-NK Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: CAR-NK Cell Therapy total market, key domestic companies, and share, (USD Million)
Global CAR-NK Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global CAR-NK Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global CAR-NK Cell Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global CAR-NK Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Artiva Biotherapeutics, Cartherics, Cytoimmune Therapeutics, Dragonfly Therapeutics, Fate Therapeutics, Glycostem Therapeutics, ImmuneBridge, ImmunityBio, Nkarta, NKGen Biotech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world CAR-NK Cell Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global CAR-NK Cell Therapy Market, By Region:
1. How big is the global CAR-NK Cell Therapy market?
2. What is the demand of the global CAR-NK Cell Therapy market?
3. What is the year over year growth of the global CAR-NK Cell Therapy market?
4. What is the total value of the global CAR-NK Cell Therapy market?
5. Who are the Major Players in the global CAR-NK Cell Therapy market?
6. What are the growth factors driving the market demand?
CAR-NK cell therapy is an advanced cellular therapy technique that combines the natural anticancer ability of natural killer (NK) cells with the specific targeting function of chimeric antigen receptors (CARs). Through genetic engineering, CAR structures capable of recognizing specific tumor antigens are introduced into NK cells, thereby enhancing their targeting ability and killing power. This therapy has shown great potential in treating various types of cancers, including hematological tumors and solid tumors. CAR-NK cell therapy has lower toxic and side effects and better safety, making it a promising supplement or alternative to CAR-T cell therapy.
Market Drivers
Superior Safety and ?Off-the-Shelf? Potential over CAR-T therapies is a critical driver. CAR-NK cells carry a significantly lower risk of cytokine release syndrome (CRS), neurotoxicity, and graft-versus-host disease (GvHD). Furthermore, they can be developed as allogeneic, ?off-the-shelf? products from healthy donors, unlike patient-specific CAR-T cells. This enables faster, more scalable, and cost-effective production.
Technological Advancements and Clinical Progress are accelerating market growth. These include the development of genetically engineered CAR-NK cells, integration of induced pluripotent stem cell (iPSC)-derived NK cells for mass production, and improved cryopreservation techniques. The pipeline is robust, with numerous companies advancing therapies into late-stage clinical trials.
This report studies the global CAR-NK Cell Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for CAR-NK Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of CAR-NK Cell Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global CAR-NK Cell Therapy total market, 2021-2032, (USD Million)
Global CAR-NK Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: CAR-NK Cell Therapy total market, key domestic companies, and share, (USD Million)
Global CAR-NK Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global CAR-NK Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global CAR-NK Cell Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global CAR-NK Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Artiva Biotherapeutics, Cartherics, Cytoimmune Therapeutics, Dragonfly Therapeutics, Fate Therapeutics, Glycostem Therapeutics, ImmuneBridge, ImmunityBio, Nkarta, NKGen Biotech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world CAR-NK Cell Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global CAR-NK Cell Therapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Cytokine Therapy
- Adoptive NK Cell Therapy
- Genetically Engineered NK Cell Therapy
- Others
- Peripheral Blood (PB)
- Umbilical Cord Blood (CB)
- Induced Pluripotent Stem Cells (iPSCs)
- NK Cell Lines (e.g., NK-92)
- First Generation
- Second/Third Generation
- Fourth Generation
- Solid Tumors
- Hematological Malignancies
- Artiva Biotherapeutics
- Cartherics
- Cytoimmune Therapeutics
- Dragonfly Therapeutics
- Fate Therapeutics
- Glycostem Therapeutics
- ImmuneBridge
- ImmunityBio
- Nkarta
- NKGen Biotech
- ONK Therapeutics
- Senti Biosciences
- Base Therapeutics
- Persongen
- Alpha Biopharma
- Guangzhou Doublle Bioproduct
- Rui Therapeutics
- Allife Medicine
- Morecell
- Simnova
- Nuwacell
1. How big is the global CAR-NK Cell Therapy market?
2. What is the demand of the global CAR-NK Cell Therapy market?
3. What is the year over year growth of the global CAR-NK Cell Therapy market?
4. What is the total value of the global CAR-NK Cell Therapy market?
5. Who are the Major Players in the global CAR-NK Cell Therapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 CAR-NK Cell Therapy Introduction
1.2 World CAR-NK Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World CAR-NK Cell Therapy Total Market by Region (by Headquarter Location)
1.3.1 World CAR-NK Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.3 China Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.4 Europe Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.5 Japan Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.8 India Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 CAR-NK Cell Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World CAR-NK Cell Therapy Consumption Value (2021-2032)
2.2 World CAR-NK Cell Therapy Consumption Value by Region
2.2.1 World CAR-NK Cell Therapy Consumption Value by Region (2021-2026)
2.2.2 World CAR-NK Cell Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States CAR-NK Cell Therapy Consumption Value (2021-2032)
2.4 China CAR-NK Cell Therapy Consumption Value (2021-2032)
2.5 Europe CAR-NK Cell Therapy Consumption Value (2021-2032)
2.6 Japan CAR-NK Cell Therapy Consumption Value (2021-2032)
2.7 South Korea CAR-NK Cell Therapy Consumption Value (2021-2032)
2.8 ASEAN CAR-NK Cell Therapy Consumption Value (2021-2032)
2.9 India CAR-NK Cell Therapy Consumption Value (2021-2032)
3 WORLD CAR-NK CELL THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World CAR-NK Cell Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global CAR-NK Cell Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for CAR-NK Cell Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for CAR-NK Cell Therapy in 2025
3.3 CAR-NK Cell Therapy Company Evaluation Quadrant
3.4 CAR-NK Cell Therapy Market: Overall Company Footprint Analysis
3.4.1 CAR-NK Cell Therapy Market: Region Footprint
3.4.2 CAR-NK Cell Therapy Market: Company Product Type Footprint
3.4.3 CAR-NK Cell Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: CAR-NK Cell Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: CAR-NK Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: CAR-NK Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: CAR-NK Cell Therapy Consumption Value Comparison
4.2.1 United States VS China: CAR-NK Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: CAR-NK Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based CAR-NK Cell Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based CAR-NK Cell Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies CAR-NK Cell Therapy Revenue, (2021-2026)
4.4 China Based Companies CAR-NK Cell Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based CAR-NK Cell Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies CAR-NK Cell Therapy Revenue, (2021-2026)
4.5 Rest of World Based CAR-NK Cell Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based CAR-NK Cell Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies CAR-NK Cell Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World CAR-NK Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Cytokine Therapy
5.2.2 Adoptive NK Cell Therapy
5.2.3 Genetically Engineered NK Cell Therapy
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World CAR-NK Cell Therapy Market Size by Type (2021-2026)
5.3.2 World CAR-NK Cell Therapy Market Size by Type (2027-2032)
5.3.3 World CAR-NK Cell Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY CELL SOURCE
6.1 World CAR-NK Cell Therapy Market Size Overview by Cell Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Cell Source
6.2.1 Peripheral Blood (PB)
6.2.2 Umbilical Cord Blood (CB)
6.2.3 Induced Pluripotent Stem Cells (iPSCs)
6.2.4 NK Cell Lines (e.g., NK-92)
6.3 Market Segment by Cell Source
6.3.1 World CAR-NK Cell Therapy Market Size by Cell Source (2021-2026)
6.3.2 World CAR-NK Cell Therapy Market Size by Cell Source (2027-2032)
6.3.3 World CAR-NK Cell Therapy Market Size Market Share by Cell Source (2027-2032)
7 MARKET ANALYSIS BY PRODUCT GENERATION
7.1 World CAR-NK Cell Therapy Market Size Overview by Product Generation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Product Generation
7.2.1 First Generation
7.2.2 Second/Third Generation
7.2.3 Fourth Generation
7.3 Market Segment by Product Generation
7.3.1 World CAR-NK Cell Therapy Market Size by Product Generation (2021-2026)
7.3.2 World CAR-NK Cell Therapy Market Size by Product Generation (2027-2032)
7.3.3 World CAR-NK Cell Therapy Market Size Market Share by Product Generation (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World CAR-NK Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Solid Tumors
8.2.2 Hematological Malignancies
8.3 Market Segment by Application
8.3.1 World CAR-NK Cell Therapy Market Size by Application (2021-2026)
8.3.2 World CAR-NK Cell Therapy Market Size by Application (2027-2032)
8.3.3 World CAR-NK Cell Therapy Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Artiva Biotherapeutics
9.1.1 Artiva Biotherapeutics Details
9.1.2 Artiva Biotherapeutics Major Business
9.1.3 Artiva Biotherapeutics CAR-NK Cell Therapy Product and Services
9.1.4 Artiva Biotherapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Artiva Biotherapeutics Recent Developments/Updates
9.1.6 Artiva Biotherapeutics Competitive Strengths & Weaknesses
9.2 Cartherics
9.2.1 Cartherics Details
9.2.2 Cartherics Major Business
9.2.3 Cartherics CAR-NK Cell Therapy Product and Services
9.2.4 Cartherics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Cartherics Recent Developments/Updates
9.2.6 Cartherics Competitive Strengths & Weaknesses
9.3 Cytoimmune Therapeutics
9.3.1 Cytoimmune Therapeutics Details
9.3.2 Cytoimmune Therapeutics Major Business
9.3.3 Cytoimmune Therapeutics CAR-NK Cell Therapy Product and Services
9.3.4 Cytoimmune Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Cytoimmune Therapeutics Recent Developments/Updates
9.3.6 Cytoimmune Therapeutics Competitive Strengths & Weaknesses
9.4 Dragonfly Therapeutics
9.4.1 Dragonfly Therapeutics Details
9.4.2 Dragonfly Therapeutics Major Business
9.4.3 Dragonfly Therapeutics CAR-NK Cell Therapy Product and Services
9.4.4 Dragonfly Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Dragonfly Therapeutics Recent Developments/Updates
9.4.6 Dragonfly Therapeutics Competitive Strengths & Weaknesses
9.5 Fate Therapeutics
9.5.1 Fate Therapeutics Details
9.5.2 Fate Therapeutics Major Business
9.5.3 Fate Therapeutics CAR-NK Cell Therapy Product and Services
9.5.4 Fate Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Fate Therapeutics Recent Developments/Updates
9.5.6 Fate Therapeutics Competitive Strengths & Weaknesses
9.6 Glycostem Therapeutics
9.6.1 Glycostem Therapeutics Details
9.6.2 Glycostem Therapeutics Major Business
9.6.3 Glycostem Therapeutics CAR-NK Cell Therapy Product and Services
9.6.4 Glycostem Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Glycostem Therapeutics Recent Developments/Updates
9.6.6 Glycostem Therapeutics Competitive Strengths & Weaknesses
9.7 ImmuneBridge
9.7.1 ImmuneBridge Details
9.7.2 ImmuneBridge Major Business
9.7.3 ImmuneBridge CAR-NK Cell Therapy Product and Services
9.7.4 ImmuneBridge CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 ImmuneBridge Recent Developments/Updates
9.7.6 ImmuneBridge Competitive Strengths & Weaknesses
9.8 ImmunityBio
9.8.1 ImmunityBio Details
9.8.2 ImmunityBio Major Business
9.8.3 ImmunityBio CAR-NK Cell Therapy Product and Services
9.8.4 ImmunityBio CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 ImmunityBio Recent Developments/Updates
9.8.6 ImmunityBio Competitive Strengths & Weaknesses
9.9 Nkarta
9.9.1 Nkarta Details
9.9.2 Nkarta Major Business
9.9.3 Nkarta CAR-NK Cell Therapy Product and Services
9.9.4 Nkarta CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Nkarta Recent Developments/Updates
9.9.6 Nkarta Competitive Strengths & Weaknesses
9.10 NKGen Biotech
9.10.1 NKGen Biotech Details
9.10.2 NKGen Biotech Major Business
9.10.3 NKGen Biotech CAR-NK Cell Therapy Product and Services
9.10.4 NKGen Biotech CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 NKGen Biotech Recent Developments/Updates
9.10.6 NKGen Biotech Competitive Strengths & Weaknesses
9.11 ONK Therapeutics
9.11.1 ONK Therapeutics Details
9.11.2 ONK Therapeutics Major Business
9.11.3 ONK Therapeutics CAR-NK Cell Therapy Product and Services
9.11.4 ONK Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 ONK Therapeutics Recent Developments/Updates
9.11.6 ONK Therapeutics Competitive Strengths & Weaknesses
9.12 Senti Biosciences
9.12.1 Senti Biosciences Details
9.12.2 Senti Biosciences Major Business
9.12.3 Senti Biosciences CAR-NK Cell Therapy Product and Services
9.12.4 Senti Biosciences CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Senti Biosciences Recent Developments/Updates
9.12.6 Senti Biosciences Competitive Strengths & Weaknesses
9.13 Base Therapeutics
9.13.1 Base Therapeutics Details
9.13.2 Base Therapeutics Major Business
9.13.3 Base Therapeutics CAR-NK Cell Therapy Product and Services
9.13.4 Base Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Base Therapeutics Recent Developments/Updates
9.13.6 Base Therapeutics Competitive Strengths & Weaknesses
9.14 Persongen
9.14.1 Persongen Details
9.14.2 Persongen Major Business
9.14.3 Persongen CAR-NK Cell Therapy Product and Services
9.14.4 Persongen CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Persongen Recent Developments/Updates
9.14.6 Persongen Competitive Strengths & Weaknesses
9.15 Alpha Biopharma
9.15.1 Alpha Biopharma Details
9.15.2 Alpha Biopharma Major Business
9.15.3 Alpha Biopharma CAR-NK Cell Therapy Product and Services
9.15.4 Alpha Biopharma CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Alpha Biopharma Recent Developments/Updates
9.15.6 Alpha Biopharma Competitive Strengths & Weaknesses
9.16 Guangzhou Doublle Bioproduct
9.16.1 Guangzhou Doublle Bioproduct Details
9.16.2 Guangzhou Doublle Bioproduct Major Business
9.16.3 Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Product and Services
9.16.4 Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Guangzhou Doublle Bioproduct Recent Developments/Updates
9.16.6 Guangzhou Doublle Bioproduct Competitive Strengths & Weaknesses
9.17 Rui Therapeutics
9.17.1 Rui Therapeutics Details
9.17.2 Rui Therapeutics Major Business
9.17.3 Rui Therapeutics CAR-NK Cell Therapy Product and Services
9.17.4 Rui Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Rui Therapeutics Recent Developments/Updates
9.17.6 Rui Therapeutics Competitive Strengths & Weaknesses
9.18 Allife Medicine
9.18.1 Allife Medicine Details
9.18.2 Allife Medicine Major Business
9.18.3 Allife Medicine CAR-NK Cell Therapy Product and Services
9.18.4 Allife Medicine CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Allife Medicine Recent Developments/Updates
9.18.6 Allife Medicine Competitive Strengths & Weaknesses
9.19 Morecell
9.19.1 Morecell Details
9.19.2 Morecell Major Business
9.19.3 Morecell CAR-NK Cell Therapy Product and Services
9.19.4 Morecell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Morecell Recent Developments/Updates
9.19.6 Morecell Competitive Strengths & Weaknesses
9.20 Simnova
9.20.1 Simnova Details
9.20.2 Simnova Major Business
9.20.3 Simnova CAR-NK Cell Therapy Product and Services
9.20.4 Simnova CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Simnova Recent Developments/Updates
9.20.6 Simnova Competitive Strengths & Weaknesses
9.21 Nuwacell
9.21.1 Nuwacell Details
9.21.2 Nuwacell Major Business
9.21.3 Nuwacell CAR-NK Cell Therapy Product and Services
9.21.4 Nuwacell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Nuwacell Recent Developments/Updates
9.21.6 Nuwacell Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 CAR-NK Cell Therapy Industry Chain
10.2 CAR-NK Cell Therapy Upstream Analysis
10.3 CAR-NK Cell Therapy Midstream Analysis
10.4 CAR-NK Cell Therapy Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 CAR-NK Cell Therapy Introduction
1.2 World CAR-NK Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World CAR-NK Cell Therapy Total Market by Region (by Headquarter Location)
1.3.1 World CAR-NK Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.3 China Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.4 Europe Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.5 Japan Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.3.8 India Based Company CAR-NK Cell Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 CAR-NK Cell Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World CAR-NK Cell Therapy Consumption Value (2021-2032)
2.2 World CAR-NK Cell Therapy Consumption Value by Region
2.2.1 World CAR-NK Cell Therapy Consumption Value by Region (2021-2026)
2.2.2 World CAR-NK Cell Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States CAR-NK Cell Therapy Consumption Value (2021-2032)
2.4 China CAR-NK Cell Therapy Consumption Value (2021-2032)
2.5 Europe CAR-NK Cell Therapy Consumption Value (2021-2032)
2.6 Japan CAR-NK Cell Therapy Consumption Value (2021-2032)
2.7 South Korea CAR-NK Cell Therapy Consumption Value (2021-2032)
2.8 ASEAN CAR-NK Cell Therapy Consumption Value (2021-2032)
2.9 India CAR-NK Cell Therapy Consumption Value (2021-2032)
3 WORLD CAR-NK CELL THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World CAR-NK Cell Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global CAR-NK Cell Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for CAR-NK Cell Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for CAR-NK Cell Therapy in 2025
3.3 CAR-NK Cell Therapy Company Evaluation Quadrant
3.4 CAR-NK Cell Therapy Market: Overall Company Footprint Analysis
3.4.1 CAR-NK Cell Therapy Market: Region Footprint
3.4.2 CAR-NK Cell Therapy Market: Company Product Type Footprint
3.4.3 CAR-NK Cell Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: CAR-NK Cell Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: CAR-NK Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: CAR-NK Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: CAR-NK Cell Therapy Consumption Value Comparison
4.2.1 United States VS China: CAR-NK Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: CAR-NK Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based CAR-NK Cell Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based CAR-NK Cell Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies CAR-NK Cell Therapy Revenue, (2021-2026)
4.4 China Based Companies CAR-NK Cell Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based CAR-NK Cell Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies CAR-NK Cell Therapy Revenue, (2021-2026)
4.5 Rest of World Based CAR-NK Cell Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based CAR-NK Cell Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies CAR-NK Cell Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World CAR-NK Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Cytokine Therapy
5.2.2 Adoptive NK Cell Therapy
5.2.3 Genetically Engineered NK Cell Therapy
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World CAR-NK Cell Therapy Market Size by Type (2021-2026)
5.3.2 World CAR-NK Cell Therapy Market Size by Type (2027-2032)
5.3.3 World CAR-NK Cell Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY CELL SOURCE
6.1 World CAR-NK Cell Therapy Market Size Overview by Cell Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Cell Source
6.2.1 Peripheral Blood (PB)
6.2.2 Umbilical Cord Blood (CB)
6.2.3 Induced Pluripotent Stem Cells (iPSCs)
6.2.4 NK Cell Lines (e.g., NK-92)
6.3 Market Segment by Cell Source
6.3.1 World CAR-NK Cell Therapy Market Size by Cell Source (2021-2026)
6.3.2 World CAR-NK Cell Therapy Market Size by Cell Source (2027-2032)
6.3.3 World CAR-NK Cell Therapy Market Size Market Share by Cell Source (2027-2032)
7 MARKET ANALYSIS BY PRODUCT GENERATION
7.1 World CAR-NK Cell Therapy Market Size Overview by Product Generation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Product Generation
7.2.1 First Generation
7.2.2 Second/Third Generation
7.2.3 Fourth Generation
7.3 Market Segment by Product Generation
7.3.1 World CAR-NK Cell Therapy Market Size by Product Generation (2021-2026)
7.3.2 World CAR-NK Cell Therapy Market Size by Product Generation (2027-2032)
7.3.3 World CAR-NK Cell Therapy Market Size Market Share by Product Generation (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World CAR-NK Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Solid Tumors
8.2.2 Hematological Malignancies
8.3 Market Segment by Application
8.3.1 World CAR-NK Cell Therapy Market Size by Application (2021-2026)
8.3.2 World CAR-NK Cell Therapy Market Size by Application (2027-2032)
8.3.3 World CAR-NK Cell Therapy Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Artiva Biotherapeutics
9.1.1 Artiva Biotherapeutics Details
9.1.2 Artiva Biotherapeutics Major Business
9.1.3 Artiva Biotherapeutics CAR-NK Cell Therapy Product and Services
9.1.4 Artiva Biotherapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Artiva Biotherapeutics Recent Developments/Updates
9.1.6 Artiva Biotherapeutics Competitive Strengths & Weaknesses
9.2 Cartherics
9.2.1 Cartherics Details
9.2.2 Cartherics Major Business
9.2.3 Cartherics CAR-NK Cell Therapy Product and Services
9.2.4 Cartherics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Cartherics Recent Developments/Updates
9.2.6 Cartherics Competitive Strengths & Weaknesses
9.3 Cytoimmune Therapeutics
9.3.1 Cytoimmune Therapeutics Details
9.3.2 Cytoimmune Therapeutics Major Business
9.3.3 Cytoimmune Therapeutics CAR-NK Cell Therapy Product and Services
9.3.4 Cytoimmune Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Cytoimmune Therapeutics Recent Developments/Updates
9.3.6 Cytoimmune Therapeutics Competitive Strengths & Weaknesses
9.4 Dragonfly Therapeutics
9.4.1 Dragonfly Therapeutics Details
9.4.2 Dragonfly Therapeutics Major Business
9.4.3 Dragonfly Therapeutics CAR-NK Cell Therapy Product and Services
9.4.4 Dragonfly Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Dragonfly Therapeutics Recent Developments/Updates
9.4.6 Dragonfly Therapeutics Competitive Strengths & Weaknesses
9.5 Fate Therapeutics
9.5.1 Fate Therapeutics Details
9.5.2 Fate Therapeutics Major Business
9.5.3 Fate Therapeutics CAR-NK Cell Therapy Product and Services
9.5.4 Fate Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Fate Therapeutics Recent Developments/Updates
9.5.6 Fate Therapeutics Competitive Strengths & Weaknesses
9.6 Glycostem Therapeutics
9.6.1 Glycostem Therapeutics Details
9.6.2 Glycostem Therapeutics Major Business
9.6.3 Glycostem Therapeutics CAR-NK Cell Therapy Product and Services
9.6.4 Glycostem Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Glycostem Therapeutics Recent Developments/Updates
9.6.6 Glycostem Therapeutics Competitive Strengths & Weaknesses
9.7 ImmuneBridge
9.7.1 ImmuneBridge Details
9.7.2 ImmuneBridge Major Business
9.7.3 ImmuneBridge CAR-NK Cell Therapy Product and Services
9.7.4 ImmuneBridge CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 ImmuneBridge Recent Developments/Updates
9.7.6 ImmuneBridge Competitive Strengths & Weaknesses
9.8 ImmunityBio
9.8.1 ImmunityBio Details
9.8.2 ImmunityBio Major Business
9.8.3 ImmunityBio CAR-NK Cell Therapy Product and Services
9.8.4 ImmunityBio CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 ImmunityBio Recent Developments/Updates
9.8.6 ImmunityBio Competitive Strengths & Weaknesses
9.9 Nkarta
9.9.1 Nkarta Details
9.9.2 Nkarta Major Business
9.9.3 Nkarta CAR-NK Cell Therapy Product and Services
9.9.4 Nkarta CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Nkarta Recent Developments/Updates
9.9.6 Nkarta Competitive Strengths & Weaknesses
9.10 NKGen Biotech
9.10.1 NKGen Biotech Details
9.10.2 NKGen Biotech Major Business
9.10.3 NKGen Biotech CAR-NK Cell Therapy Product and Services
9.10.4 NKGen Biotech CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 NKGen Biotech Recent Developments/Updates
9.10.6 NKGen Biotech Competitive Strengths & Weaknesses
9.11 ONK Therapeutics
9.11.1 ONK Therapeutics Details
9.11.2 ONK Therapeutics Major Business
9.11.3 ONK Therapeutics CAR-NK Cell Therapy Product and Services
9.11.4 ONK Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 ONK Therapeutics Recent Developments/Updates
9.11.6 ONK Therapeutics Competitive Strengths & Weaknesses
9.12 Senti Biosciences
9.12.1 Senti Biosciences Details
9.12.2 Senti Biosciences Major Business
9.12.3 Senti Biosciences CAR-NK Cell Therapy Product and Services
9.12.4 Senti Biosciences CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Senti Biosciences Recent Developments/Updates
9.12.6 Senti Biosciences Competitive Strengths & Weaknesses
9.13 Base Therapeutics
9.13.1 Base Therapeutics Details
9.13.2 Base Therapeutics Major Business
9.13.3 Base Therapeutics CAR-NK Cell Therapy Product and Services
9.13.4 Base Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Base Therapeutics Recent Developments/Updates
9.13.6 Base Therapeutics Competitive Strengths & Weaknesses
9.14 Persongen
9.14.1 Persongen Details
9.14.2 Persongen Major Business
9.14.3 Persongen CAR-NK Cell Therapy Product and Services
9.14.4 Persongen CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Persongen Recent Developments/Updates
9.14.6 Persongen Competitive Strengths & Weaknesses
9.15 Alpha Biopharma
9.15.1 Alpha Biopharma Details
9.15.2 Alpha Biopharma Major Business
9.15.3 Alpha Biopharma CAR-NK Cell Therapy Product and Services
9.15.4 Alpha Biopharma CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Alpha Biopharma Recent Developments/Updates
9.15.6 Alpha Biopharma Competitive Strengths & Weaknesses
9.16 Guangzhou Doublle Bioproduct
9.16.1 Guangzhou Doublle Bioproduct Details
9.16.2 Guangzhou Doublle Bioproduct Major Business
9.16.3 Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Product and Services
9.16.4 Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Guangzhou Doublle Bioproduct Recent Developments/Updates
9.16.6 Guangzhou Doublle Bioproduct Competitive Strengths & Weaknesses
9.17 Rui Therapeutics
9.17.1 Rui Therapeutics Details
9.17.2 Rui Therapeutics Major Business
9.17.3 Rui Therapeutics CAR-NK Cell Therapy Product and Services
9.17.4 Rui Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Rui Therapeutics Recent Developments/Updates
9.17.6 Rui Therapeutics Competitive Strengths & Weaknesses
9.18 Allife Medicine
9.18.1 Allife Medicine Details
9.18.2 Allife Medicine Major Business
9.18.3 Allife Medicine CAR-NK Cell Therapy Product and Services
9.18.4 Allife Medicine CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Allife Medicine Recent Developments/Updates
9.18.6 Allife Medicine Competitive Strengths & Weaknesses
9.19 Morecell
9.19.1 Morecell Details
9.19.2 Morecell Major Business
9.19.3 Morecell CAR-NK Cell Therapy Product and Services
9.19.4 Morecell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Morecell Recent Developments/Updates
9.19.6 Morecell Competitive Strengths & Weaknesses
9.20 Simnova
9.20.1 Simnova Details
9.20.2 Simnova Major Business
9.20.3 Simnova CAR-NK Cell Therapy Product and Services
9.20.4 Simnova CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Simnova Recent Developments/Updates
9.20.6 Simnova Competitive Strengths & Weaknesses
9.21 Nuwacell
9.21.1 Nuwacell Details
9.21.2 Nuwacell Major Business
9.21.3 Nuwacell CAR-NK Cell Therapy Product and Services
9.21.4 Nuwacell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Nuwacell Recent Developments/Updates
9.21.6 Nuwacell Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 CAR-NK Cell Therapy Industry Chain
10.2 CAR-NK Cell Therapy Upstream Analysis
10.3 CAR-NK Cell Therapy Midstream Analysis
10.4 CAR-NK Cell Therapy Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World CAR-NK Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World CAR-NK Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World CAR-NK Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World CAR-NK Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World CAR-NK Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World CAR-NK Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World CAR-NK Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World CAR-NK Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World CAR-NK Cell Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key CAR-NK Cell Therapy Players in 2025
Table 12. World CAR-NK Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global CAR-NK Cell Therapy Company Evaluation Quadrant
Table 14. Head Office of Key CAR-NK Cell Therapy Players
Table 15. CAR-NK Cell Therapy Market: Company Product Type Footprint
Table 16. CAR-NK Cell Therapy Market: Company Product Application Footprint
Table 17. CAR-NK Cell Therapy Mergers & Acquisitions Activity
Table 18. United States VS China CAR-NK Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China CAR-NK Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based CAR-NK Cell Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies CAR-NK Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies CAR-NK Cell Therapy Revenue Market Share (2021-2026)
Table 23. China Based CAR-NK Cell Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies CAR-NK Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies CAR-NK Cell Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based CAR-NK Cell Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies CAR-NK Cell Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies CAR-NK Cell Therapy Revenue Market Share (2021-2026)
Table 29. World CAR-NK Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World CAR-NK Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World CAR-NK Cell Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World CAR-NK Cell Therapy Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Table 33. World CAR-NK Cell Therapy Market Size Value by Cell Source (2021-2026) & (USD Million)
Table 34. World CAR-NK Cell Therapy Market Size by Cell Source (2027-2032) & (USD Million)
Table 35. World CAR-NK Cell Therapy Market Size by Product Generation, (USD Million), 2021 & 2025 & 2032
Table 36. World CAR-NK Cell Therapy Market Size Value by Product Generation (2021-2026) & (USD Million)
Table 37. World CAR-NK Cell Therapy Market Size by Product Generation (2027-2032) & (USD Million)
Table 38. World CAR-NK Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World CAR-NK Cell Therapy Market Size by Application (2021-2026) & (USD Million)
Table 40. World CAR-NK Cell Therapy Market Size by Application (2027-2032) & (USD Million)
Table 41. Artiva Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 42. Artiva Biotherapeutics Major Business
Table 43. Artiva Biotherapeutics CAR-NK Cell Therapy Product and Services
Table 44. Artiva Biotherapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Artiva Biotherapeutics Recent Developments/Updates
Table 46. Artiva Biotherapeutics Competitive Strengths & Weaknesses
Table 47. Cartherics Basic Information, Manufacturing Base and Competitors
Table 48. Cartherics Major Business
Table 49. Cartherics CAR-NK Cell Therapy Product and Services
Table 50. Cartherics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Cartherics Recent Developments/Updates
Table 52. Cartherics Competitive Strengths & Weaknesses
Table 53. Cytoimmune Therapeutics Basic Information, Manufacturing Base and Competitors
Table 54. Cytoimmune Therapeutics Major Business
Table 55. Cytoimmune Therapeutics CAR-NK Cell Therapy Product and Services
Table 56. Cytoimmune Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Cytoimmune Therapeutics Recent Developments/Updates
Table 58. Cytoimmune Therapeutics Competitive Strengths & Weaknesses
Table 59. Dragonfly Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Dragonfly Therapeutics Major Business
Table 61. Dragonfly Therapeutics CAR-NK Cell Therapy Product and Services
Table 62. Dragonfly Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Dragonfly Therapeutics Recent Developments/Updates
Table 64. Dragonfly Therapeutics Competitive Strengths & Weaknesses
Table 65. Fate Therapeutics Basic Information, Manufacturing Base and Competitors
Table 66. Fate Therapeutics Major Business
Table 67. Fate Therapeutics CAR-NK Cell Therapy Product and Services
Table 68. Fate Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Fate Therapeutics Recent Developments/Updates
Table 70. Fate Therapeutics Competitive Strengths & Weaknesses
Table 71. Glycostem Therapeutics Basic Information, Manufacturing Base and Competitors
Table 72. Glycostem Therapeutics Major Business
Table 73. Glycostem Therapeutics CAR-NK Cell Therapy Product and Services
Table 74. Glycostem Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Glycostem Therapeutics Recent Developments/Updates
Table 76. Glycostem Therapeutics Competitive Strengths & Weaknesses
Table 77. ImmuneBridge Basic Information, Manufacturing Base and Competitors
Table 78. ImmuneBridge Major Business
Table 79. ImmuneBridge CAR-NK Cell Therapy Product and Services
Table 80. ImmuneBridge CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. ImmuneBridge Recent Developments/Updates
Table 82. ImmuneBridge Competitive Strengths & Weaknesses
Table 83. ImmunityBio Basic Information, Manufacturing Base and Competitors
Table 84. ImmunityBio Major Business
Table 85. ImmunityBio CAR-NK Cell Therapy Product and Services
Table 86. ImmunityBio CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. ImmunityBio Recent Developments/Updates
Table 88. ImmunityBio Competitive Strengths & Weaknesses
Table 89. Nkarta Basic Information, Manufacturing Base and Competitors
Table 90. Nkarta Major Business
Table 91. Nkarta CAR-NK Cell Therapy Product and Services
Table 92. Nkarta CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Nkarta Recent Developments/Updates
Table 94. Nkarta Competitive Strengths & Weaknesses
Table 95. NKGen Biotech Basic Information, Manufacturing Base and Competitors
Table 96. NKGen Biotech Major Business
Table 97. NKGen Biotech CAR-NK Cell Therapy Product and Services
Table 98. NKGen Biotech CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. NKGen Biotech Recent Developments/Updates
Table 100. NKGen Biotech Competitive Strengths & Weaknesses
Table 101. ONK Therapeutics Basic Information, Manufacturing Base and Competitors
Table 102. ONK Therapeutics Major Business
Table 103. ONK Therapeutics CAR-NK Cell Therapy Product and Services
Table 104. ONK Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. ONK Therapeutics Recent Developments/Updates
Table 106. ONK Therapeutics Competitive Strengths & Weaknesses
Table 107. Senti Biosciences Basic Information, Manufacturing Base and Competitors
Table 108. Senti Biosciences Major Business
Table 109. Senti Biosciences CAR-NK Cell Therapy Product and Services
Table 110. Senti Biosciences CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Senti Biosciences Recent Developments/Updates
Table 112. Senti Biosciences Competitive Strengths & Weaknesses
Table 113. Base Therapeutics Basic Information, Manufacturing Base and Competitors
Table 114. Base Therapeutics Major Business
Table 115. Base Therapeutics CAR-NK Cell Therapy Product and Services
Table 116. Base Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Base Therapeutics Recent Developments/Updates
Table 118. Base Therapeutics Competitive Strengths & Weaknesses
Table 119. Persongen Basic Information, Manufacturing Base and Competitors
Table 120. Persongen Major Business
Table 121. Persongen CAR-NK Cell Therapy Product and Services
Table 122. Persongen CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Persongen Recent Developments/Updates
Table 124. Persongen Competitive Strengths & Weaknesses
Table 125. Alpha Biopharma Basic Information, Manufacturing Base and Competitors
Table 126. Alpha Biopharma Major Business
Table 127. Alpha Biopharma CAR-NK Cell Therapy Product and Services
Table 128. Alpha Biopharma CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Alpha Biopharma Recent Developments/Updates
Table 130. Alpha Biopharma Competitive Strengths & Weaknesses
Table 131. Guangzhou Doublle Bioproduct Basic Information, Manufacturing Base and Competitors
Table 132. Guangzhou Doublle Bioproduct Major Business
Table 133. Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Product and Services
Table 134. Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Guangzhou Doublle Bioproduct Recent Developments/Updates
Table 136. Guangzhou Doublle Bioproduct Competitive Strengths & Weaknesses
Table 137. Rui Therapeutics Basic Information, Manufacturing Base and Competitors
Table 138. Rui Therapeutics Major Business
Table 139. Rui Therapeutics CAR-NK Cell Therapy Product and Services
Table 140. Rui Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Rui Therapeutics Recent Developments/Updates
Table 142. Rui Therapeutics Competitive Strengths & Weaknesses
Table 143. Allife Medicine Basic Information, Manufacturing Base and Competitors
Table 144. Allife Medicine Major Business
Table 145. Allife Medicine CAR-NK Cell Therapy Product and Services
Table 146. Allife Medicine CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Allife Medicine Recent Developments/Updates
Table 148. Allife Medicine Competitive Strengths & Weaknesses
Table 149. Morecell Basic Information, Manufacturing Base and Competitors
Table 150. Morecell Major Business
Table 151. Morecell CAR-NK Cell Therapy Product and Services
Table 152. Morecell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Morecell Recent Developments/Updates
Table 154. Morecell Competitive Strengths & Weaknesses
Table 155. Simnova Basic Information, Manufacturing Base and Competitors
Table 156. Simnova Major Business
Table 157. Simnova CAR-NK Cell Therapy Product and Services
Table 158. Simnova CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Simnova Recent Developments/Updates
Table 160. Simnova Competitive Strengths & Weaknesses
Table 161. Nuwacell Basic Information, Manufacturing Base and Competitors
Table 162. Nuwacell Major Business
Table 163. Nuwacell CAR-NK Cell Therapy Product and Services
Table 164. Nuwacell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Nuwacell Recent Developments/Updates
Table 166. Nuwacell Competitive Strengths & Weaknesses
Table 167. Global Key Players of CAR-NK Cell Therapy Upstream (Raw Materials)
Table 168. Global CAR-NK Cell Therapy Typical Customers
Table 1. World CAR-NK Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World CAR-NK Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World CAR-NK Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World CAR-NK Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World CAR-NK Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World CAR-NK Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World CAR-NK Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World CAR-NK Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World CAR-NK Cell Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key CAR-NK Cell Therapy Players in 2025
Table 12. World CAR-NK Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global CAR-NK Cell Therapy Company Evaluation Quadrant
Table 14. Head Office of Key CAR-NK Cell Therapy Players
Table 15. CAR-NK Cell Therapy Market: Company Product Type Footprint
Table 16. CAR-NK Cell Therapy Market: Company Product Application Footprint
Table 17. CAR-NK Cell Therapy Mergers & Acquisitions Activity
Table 18. United States VS China CAR-NK Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China CAR-NK Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based CAR-NK Cell Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies CAR-NK Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies CAR-NK Cell Therapy Revenue Market Share (2021-2026)
Table 23. China Based CAR-NK Cell Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies CAR-NK Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies CAR-NK Cell Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based CAR-NK Cell Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies CAR-NK Cell Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies CAR-NK Cell Therapy Revenue Market Share (2021-2026)
Table 29. World CAR-NK Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World CAR-NK Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World CAR-NK Cell Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World CAR-NK Cell Therapy Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Table 33. World CAR-NK Cell Therapy Market Size Value by Cell Source (2021-2026) & (USD Million)
Table 34. World CAR-NK Cell Therapy Market Size by Cell Source (2027-2032) & (USD Million)
Table 35. World CAR-NK Cell Therapy Market Size by Product Generation, (USD Million), 2021 & 2025 & 2032
Table 36. World CAR-NK Cell Therapy Market Size Value by Product Generation (2021-2026) & (USD Million)
Table 37. World CAR-NK Cell Therapy Market Size by Product Generation (2027-2032) & (USD Million)
Table 38. World CAR-NK Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World CAR-NK Cell Therapy Market Size by Application (2021-2026) & (USD Million)
Table 40. World CAR-NK Cell Therapy Market Size by Application (2027-2032) & (USD Million)
Table 41. Artiva Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 42. Artiva Biotherapeutics Major Business
Table 43. Artiva Biotherapeutics CAR-NK Cell Therapy Product and Services
Table 44. Artiva Biotherapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Artiva Biotherapeutics Recent Developments/Updates
Table 46. Artiva Biotherapeutics Competitive Strengths & Weaknesses
Table 47. Cartherics Basic Information, Manufacturing Base and Competitors
Table 48. Cartherics Major Business
Table 49. Cartherics CAR-NK Cell Therapy Product and Services
Table 50. Cartherics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Cartherics Recent Developments/Updates
Table 52. Cartherics Competitive Strengths & Weaknesses
Table 53. Cytoimmune Therapeutics Basic Information, Manufacturing Base and Competitors
Table 54. Cytoimmune Therapeutics Major Business
Table 55. Cytoimmune Therapeutics CAR-NK Cell Therapy Product and Services
Table 56. Cytoimmune Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Cytoimmune Therapeutics Recent Developments/Updates
Table 58. Cytoimmune Therapeutics Competitive Strengths & Weaknesses
Table 59. Dragonfly Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Dragonfly Therapeutics Major Business
Table 61. Dragonfly Therapeutics CAR-NK Cell Therapy Product and Services
Table 62. Dragonfly Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Dragonfly Therapeutics Recent Developments/Updates
Table 64. Dragonfly Therapeutics Competitive Strengths & Weaknesses
Table 65. Fate Therapeutics Basic Information, Manufacturing Base and Competitors
Table 66. Fate Therapeutics Major Business
Table 67. Fate Therapeutics CAR-NK Cell Therapy Product and Services
Table 68. Fate Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Fate Therapeutics Recent Developments/Updates
Table 70. Fate Therapeutics Competitive Strengths & Weaknesses
Table 71. Glycostem Therapeutics Basic Information, Manufacturing Base and Competitors
Table 72. Glycostem Therapeutics Major Business
Table 73. Glycostem Therapeutics CAR-NK Cell Therapy Product and Services
Table 74. Glycostem Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Glycostem Therapeutics Recent Developments/Updates
Table 76. Glycostem Therapeutics Competitive Strengths & Weaknesses
Table 77. ImmuneBridge Basic Information, Manufacturing Base and Competitors
Table 78. ImmuneBridge Major Business
Table 79. ImmuneBridge CAR-NK Cell Therapy Product and Services
Table 80. ImmuneBridge CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. ImmuneBridge Recent Developments/Updates
Table 82. ImmuneBridge Competitive Strengths & Weaknesses
Table 83. ImmunityBio Basic Information, Manufacturing Base and Competitors
Table 84. ImmunityBio Major Business
Table 85. ImmunityBio CAR-NK Cell Therapy Product and Services
Table 86. ImmunityBio CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. ImmunityBio Recent Developments/Updates
Table 88. ImmunityBio Competitive Strengths & Weaknesses
Table 89. Nkarta Basic Information, Manufacturing Base and Competitors
Table 90. Nkarta Major Business
Table 91. Nkarta CAR-NK Cell Therapy Product and Services
Table 92. Nkarta CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Nkarta Recent Developments/Updates
Table 94. Nkarta Competitive Strengths & Weaknesses
Table 95. NKGen Biotech Basic Information, Manufacturing Base and Competitors
Table 96. NKGen Biotech Major Business
Table 97. NKGen Biotech CAR-NK Cell Therapy Product and Services
Table 98. NKGen Biotech CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. NKGen Biotech Recent Developments/Updates
Table 100. NKGen Biotech Competitive Strengths & Weaknesses
Table 101. ONK Therapeutics Basic Information, Manufacturing Base and Competitors
Table 102. ONK Therapeutics Major Business
Table 103. ONK Therapeutics CAR-NK Cell Therapy Product and Services
Table 104. ONK Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. ONK Therapeutics Recent Developments/Updates
Table 106. ONK Therapeutics Competitive Strengths & Weaknesses
Table 107. Senti Biosciences Basic Information, Manufacturing Base and Competitors
Table 108. Senti Biosciences Major Business
Table 109. Senti Biosciences CAR-NK Cell Therapy Product and Services
Table 110. Senti Biosciences CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Senti Biosciences Recent Developments/Updates
Table 112. Senti Biosciences Competitive Strengths & Weaknesses
Table 113. Base Therapeutics Basic Information, Manufacturing Base and Competitors
Table 114. Base Therapeutics Major Business
Table 115. Base Therapeutics CAR-NK Cell Therapy Product and Services
Table 116. Base Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Base Therapeutics Recent Developments/Updates
Table 118. Base Therapeutics Competitive Strengths & Weaknesses
Table 119. Persongen Basic Information, Manufacturing Base and Competitors
Table 120. Persongen Major Business
Table 121. Persongen CAR-NK Cell Therapy Product and Services
Table 122. Persongen CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Persongen Recent Developments/Updates
Table 124. Persongen Competitive Strengths & Weaknesses
Table 125. Alpha Biopharma Basic Information, Manufacturing Base and Competitors
Table 126. Alpha Biopharma Major Business
Table 127. Alpha Biopharma CAR-NK Cell Therapy Product and Services
Table 128. Alpha Biopharma CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Alpha Biopharma Recent Developments/Updates
Table 130. Alpha Biopharma Competitive Strengths & Weaknesses
Table 131. Guangzhou Doublle Bioproduct Basic Information, Manufacturing Base and Competitors
Table 132. Guangzhou Doublle Bioproduct Major Business
Table 133. Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Product and Services
Table 134. Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Guangzhou Doublle Bioproduct Recent Developments/Updates
Table 136. Guangzhou Doublle Bioproduct Competitive Strengths & Weaknesses
Table 137. Rui Therapeutics Basic Information, Manufacturing Base and Competitors
Table 138. Rui Therapeutics Major Business
Table 139. Rui Therapeutics CAR-NK Cell Therapy Product and Services
Table 140. Rui Therapeutics CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Rui Therapeutics Recent Developments/Updates
Table 142. Rui Therapeutics Competitive Strengths & Weaknesses
Table 143. Allife Medicine Basic Information, Manufacturing Base and Competitors
Table 144. Allife Medicine Major Business
Table 145. Allife Medicine CAR-NK Cell Therapy Product and Services
Table 146. Allife Medicine CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Allife Medicine Recent Developments/Updates
Table 148. Allife Medicine Competitive Strengths & Weaknesses
Table 149. Morecell Basic Information, Manufacturing Base and Competitors
Table 150. Morecell Major Business
Table 151. Morecell CAR-NK Cell Therapy Product and Services
Table 152. Morecell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Morecell Recent Developments/Updates
Table 154. Morecell Competitive Strengths & Weaknesses
Table 155. Simnova Basic Information, Manufacturing Base and Competitors
Table 156. Simnova Major Business
Table 157. Simnova CAR-NK Cell Therapy Product and Services
Table 158. Simnova CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Simnova Recent Developments/Updates
Table 160. Simnova Competitive Strengths & Weaknesses
Table 161. Nuwacell Basic Information, Manufacturing Base and Competitors
Table 162. Nuwacell Major Business
Table 163. Nuwacell CAR-NK Cell Therapy Product and Services
Table 164. Nuwacell CAR-NK Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Nuwacell Recent Developments/Updates
Table 166. Nuwacell Competitive Strengths & Weaknesses
Table 167. Global Key Players of CAR-NK Cell Therapy Upstream (Raw Materials)
Table 168. Global CAR-NK Cell Therapy Typical Customers
LIST OF FIGURES
Figure 1. CAR-NK Cell Therapy Picture
Figure 2. World CAR-NK Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World CAR-NK Cell Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World CAR-NK Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World CAR-NK Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 13. CAR-NK Cell Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World CAR-NK Cell Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of CAR-NK Cell Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for CAR-NK Cell Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for CAR-NK Cell Therapy Markets in 2025
Figure 27. United States VS China: CAR-NK Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: CAR-NK Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World CAR-NK Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World CAR-NK Cell Therapy Market Size Market Share by Type in 2025
Figure 31. Cytokine Therapy
Figure 32. Adoptive NK Cell Therapy
Figure 33. Genetically Engineered NK Cell Therapy
Figure 34. Others
Figure 35. World CAR-NK Cell Therapy Market Size Market Share by Type (2021-2032)
Figure 36. World CAR-NK Cell Therapy Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 37. World CAR-NK Cell Therapy Market Size Market Share by Cell Source in 2025
Figure 38. Peripheral Blood (PB)
Figure 39. Umbilical Cord Blood (CB)
Figure 40. Induced Pluripotent Stem Cells (iPSCs)
Figure 41. NK Cell Lines (e.g., NK-92)
Figure 42. World CAR-NK Cell Therapy Market Size Market Share by Cell Source (2021-2032)
Figure 43. World CAR-NK Cell Therapy Market Size by Product Generation, (USD Million), 2021 & 2025 & 2032
Figure 44. World CAR-NK Cell Therapy Market Size Market Share by Product Generation in 2025
Figure 45. First Generation
Figure 46. Second/Third Generation
Figure 47. Fourth Generation
Figure 48. World CAR-NK Cell Therapy Market Size Market Share by Product Generation (2021-2032)
Figure 49. World CAR-NK Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World CAR-NK Cell Therapy Market Size Market Share by Application in 2025
Figure 51. Solid Tumors
Figure 52. Hematological Malignancies
Figure 53. World CAR-NK Cell Therapy Market Size Market Share by Application (2021-2032)
Figure 54. CAR-NK Cell Therapy Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source
Figure 1. CAR-NK Cell Therapy Picture
Figure 2. World CAR-NK Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World CAR-NK Cell Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World CAR-NK Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World CAR-NK Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company CAR-NK Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 13. CAR-NK Cell Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World CAR-NK Cell Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India CAR-NK Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of CAR-NK Cell Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for CAR-NK Cell Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for CAR-NK Cell Therapy Markets in 2025
Figure 27. United States VS China: CAR-NK Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: CAR-NK Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World CAR-NK Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World CAR-NK Cell Therapy Market Size Market Share by Type in 2025
Figure 31. Cytokine Therapy
Figure 32. Adoptive NK Cell Therapy
Figure 33. Genetically Engineered NK Cell Therapy
Figure 34. Others
Figure 35. World CAR-NK Cell Therapy Market Size Market Share by Type (2021-2032)
Figure 36. World CAR-NK Cell Therapy Market Size by Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 37. World CAR-NK Cell Therapy Market Size Market Share by Cell Source in 2025
Figure 38. Peripheral Blood (PB)
Figure 39. Umbilical Cord Blood (CB)
Figure 40. Induced Pluripotent Stem Cells (iPSCs)
Figure 41. NK Cell Lines (e.g., NK-92)
Figure 42. World CAR-NK Cell Therapy Market Size Market Share by Cell Source (2021-2032)
Figure 43. World CAR-NK Cell Therapy Market Size by Product Generation, (USD Million), 2021 & 2025 & 2032
Figure 44. World CAR-NK Cell Therapy Market Size Market Share by Product Generation in 2025
Figure 45. First Generation
Figure 46. Second/Third Generation
Figure 47. Fourth Generation
Figure 48. World CAR-NK Cell Therapy Market Size Market Share by Product Generation (2021-2032)
Figure 49. World CAR-NK Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World CAR-NK Cell Therapy Market Size Market Share by Application in 2025
Figure 51. Solid Tumors
Figure 52. Hematological Malignancies
Figure 53. World CAR-NK Cell Therapy Market Size Market Share by Application (2021-2032)
Figure 54. CAR-NK Cell Therapy Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source
